Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-08 Phase I Study in Healthy Participants
NCT07021157Phase 1Recruiting
- Sponsor
- Consun Pharmaceutical Group
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic kidney disease (CKD) comparing SK-08 with Placebo (2 arms). Primary endpoint: Safety Evaluation at Day 12. Started Mar 2025; status: recruiting.
02
Drugs
SK-08
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07021157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021157.